Oncology

  • Study supports NCCN recommendations on risk-reducing salpingo-oophorectomy

    on March 28th, 2017
    AT THE ANNUAL MEETING ON WOMEN’S CANCER NATIONAL HARBOR, MD (FRONTLINE MEDICAL NEWS) – A large hereditary cancer study supports National Comprehensive Cancer Network guidance to consider risk-reducing salpingo-oophorectomy (RRSO) between ages 45 and 50 years for women with BRIP1, RAD51C, or RAD5[...]
  • PARP inhibitor approved as maintenance for recurrent ovarian cancer

    on March 28th, 2017
    The Food and Drug Administration has approved niraparib, a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemothera[...]
  • Advanced CLL treatment approach depends on comorbidity burden

    on March 27th, 2017
    EXPERT ANALYSIS FROM THE NCCN ANNUAL CONFERENCE ORLANDO (FRONTLINE MEDICAL NEWS) – The choice of first-line therapy in symptomatic chronic lymphocytic leukemia patients depends largely on comorbidity burden, Andrew D. Zelenetz, MD, PhD, said at the annual conference of the National Comprehensive C[...]
  • Disease site determines QOL in recurrent rectal cancer

    on March 27th, 2017
    AT SSO 2017 SEATTLE (FRONTLINE MEDICAL NEWS)– Disease anatomy is the main determinant of subsequent quality of life (QOL) in patients with locally recurrent rectal cancer at both base line and in the long term, according to findings presented at the annual Society of Surgical Oncology Cancer Sympo[...]
  • NCCN: Myelofibrosis guideline is first in series on MPNs

    on March 27th, 2017
    AT THE NCCN ANNUAL CONFERENCE ORLANDO (FRONTLINE MEDICAL NEWS) – A guideline published late last year for the diagnostic work-up of myeloproliferative neoplasms and for the management of myelofibrosis in particular is just the first in a series of National Comprehensive Cancer Network guidelines o[...]
  • Complete resection tied to improved survival in low-grade serous ovarian cancer

    on March 27th, 2017
    NATIONAL HARBOR, MD. (FRONTLINE MEDICAL NEWS) – Surgical resection to the point of no residual macroscopic disease significantly improved survival among patients with low-grade serous ovarian carcinoma, based on the findings of a large multicenter retrospective cohort study. Adjuvant platinum-base[...]
  • Adding Pap to plasma testing boosted detection of ovarian tumors

    on March 27th, 2017
    NATIONAL HARBOR, MD. (FRONTLINE MEDICAL NEWS) – Combining a liquid-based Pap smear and cell-free DNA plasma testing can boost the sensitivity of screening for primary ovarian tumors, based on the results of a prospective study of 201 patients. The approach, however, was most sensitive when women a[...]
  • Peptide vaccine shows early promise in ovarian, endometrial cancers

    on March 27th, 2017
    NATIONAL HARBOR, MD. – The folate-binding protein vaccine E39+GM-CSF was well tolerated and exhibited a statistically significant, dose-dependent effect on recurrence and disease-free survival among patients with remitted primary ovarian or endometrial cancer, according to the results of a small p[...]
  • Preoperative VTEs occurred in 10% of cancer patients

    on March 27th, 2017
    AT SSO 2017 SEATTLE (FRONTLINE MEDICAL NEWS)– Venous thromboembolism (VTE) is common in cancer, but 10% of asymptomatic patients undergoing major oncologic surgery have a preoperative VTE, according to findings presented at the annual Society of Surgical Oncology Cancer Symposium. The incidence of[...]
  • FDA approves first treatment for metastatic Merkel cell carcinoma

    on March 24th, 2017
    The Food and Drug Administration has granted accelerated approval to avelumab for the treatment of metastatic Merkel cell carcinoma (MCC) in adult and pediatric patients aged 12 years and older. Avelumab, a programmed death-ligand 1 (PD-L1)–blocking human IgG1 lambda monoclonal antibody, is the fi[...]
  • Unavoidable, random DNA replication errors are the most common cancer drivers

    on March 23rd, 2017
    Up to two-thirds of the mutations that drive human cancers may be due to DNA replication errors in normally dividing stem cells, not by inherited or environmentally induced mutations, according to a mathematical modeling study. The proportion of replication error-driven mutations varied widely among[...]
  • No link between methylation, survival in ovarian cancer

    on March 23rd, 2017
    AT THE ANNUAL MEETING ON WOMEN’S CANCER NATIONAL HARBOR, MD. (FRONTLINE MEDICAL NEWS) – Unlike mutation, methylation of homologous recombination DNA repair pathway genes was not linked to longer survival or platinum sensitivity in high-grade serous ovarian cancer, according to molecular and clin[...]
  • Experts warn against readmissions as sole quality measure in ovarian cancer

    on March 22nd, 2017
    AT THE ANNUAL MEETING ON WOMEN’S CANCER NATIONAL HARBOR, MD. (FRONTLINE MEDICAL NEWS) – For patients with ovarian cancer, focusing solely on hospital readmission rates as a quality measure might worsen long-term outcomes while unfairly penalizing the best hospitals, suggest the results of two an[...]
Back to top